Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 14/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21885713 | 0.81 | XDH (0.61) | XDHBACE1HSD17B10CYP3A4BLM | |
| SCHEMBL25367941 | 0.79 | XDH (0.59) | XDHBACE1CYP3A4BLM | |
| SCHEMBL2403432 | 0.76 | XDH (1.00) | XDHBACE1 | |
| SCHEMBL4504337 | 0.73 | XDH (0.69) | XDH | |
| SCHEMBL4146196 | 0.73 | XDH (0.65) | XDHBACE1 | |
| SCHEMBL6641245 | 0.71 | XDH (0.51) | XDH | |
| SCHEMBL4133983 | 0.70 | BACE1 (0.55) | BACE1HSD17B10 | |
| SCHEMBL22030566 | 0.68 | IDO1 (0.47) | HSD17B10 | |
| SCHEMBL5381098 | 0.68 | XDH (0.72) | XDH | |
| SCHEMBL21884546 | 0.68 | AGPAT2 (0.49) | XDHCYP3A4BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| CN-101084199-A | Substituted amino-compounds and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-101084198-A | Substituted amino-pyrimidones and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| EP-1802587-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | XDH 951/4885BACE1 3/4885HSD17B10 2053/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | XDH 259/4885BACE1 4/4885HSD17B10 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.